What was the primary purpose of this 8-K filing?

The primary purpose was to report MetLife's entry into a material definitive agreement, specifically a Replacement Capital Covenant, and to disclose the completion of a private placement financing of $700 million through its subsidiary, MetLife Capital Trust IV, involving Exchangeable Surplus Trust Securities (X-SURPS).

What is the Replacement Capital Covenant and why is it important for investors?

The Replacement Capital Covenant is an agreement where MetLife commits not to repay, redeem, or purchase the X-SURPS or the subsequent Junior Subordinated Debentures before December 15, 2057, unless specific conditions are met, primarily related to issuing replacement capital securities. This covenant is crucial for investors holding MetLife's designated senior long-term indebtedness as it helps maintain the company's capital structure and debt servicing capacity.

MET 8-K: Material Agreements, Financial Events & More

Q: What are X-SURPS and what is their significance?

X-SURPS are 7.875% Fixed-to-Floating Rate Exchangeable Surplus Trust Securities issued by MetLife Capital Trust IV. They are designed to be exchangeable into MetLife's 7.875% Fixed-to-Floating Rate Junior Subordinated Debentures due 2067. This structure allows MetLife to raise capital while providing flexibility in its debt management.

Q: Are these securities registered with the SEC?

No, the X-SURPS were offered and sold in an unregistered private placement under Rule 144A, exempt from registration under the Securities Act of 1933. They were offered only to Qualified Institutional Buyers and Qualified Purchasers.

Summary

MetLife, Inc. has announced the completion of a private placement financing through its subsidiary, MetLife Capital Trust IV, raising $700 million in 7.875% Fixed-to-Floating Rate Exchangeable Surplus Trust Securities (X-SURPS). These securities are designed to be exchangeable into MetLife's 7.875% Fixed-to-Floating Rate Junior Subordinated Debentures due 2067. This transaction is being conducted under Rule 144A, targeting Qualified Institutional Buyers and Qualified Purchasers, and is exempt from registration under the Securities Act. In conjunction with this offering, MetLife has entered into a Replacement Capital Covenant. This covenant, effective until December 15, 2057, restricts MetLife and its subsidiaries from repaying, redeeming, or purchasing the X-SURPS (prior to exchange) and the Junior Subordinated Debentures (post-exchange) unless funded by the proceeds from issuing specific replacement capital securities, subject to defined terms. This covenant aims to protect the interests of holders of certain senior long-term indebtedness by ensuring the sustainability of the capital structure.

Key Highlights

1Completion of a $700 million private placement of X-SURPS by MetLife Capital Trust IV.
2X-SURPS are exchangeable into MetLife's 7.875% Fixed-to-Floating Rate Junior Subordinated Debentures due 2067.
3Transaction conducted as an unregistered offering under Rule 144A, targeting Qualified Institutional Buyers and Qualified Purchasers.
4Entry into a Replacement Capital Covenant to protect holders of certain senior long-term debt.
5The Covenant restricts early repayment/redemption of the X-SURPS and Junior Subordinated Debentures until December 15, 2057, unless specific replacement capital is used.
6X-SURPS represent interests in the Trust, whose assets include 7.375% Surplus Notes from Metropolitan Life Insurance Company.

METLIFE INC 8-K Report, Material Agreement (Dec 12, 2007)

Summary

Key Highlights

Frequently Asked Questions